ANAPTYSBIO, INC (ANAB) Stock
ANAB has an Alpha Score of 68 out of 100 (moderate), computed on Nov 11, 2026 from 3 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported ANAB in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Millennium Management's at $54.49M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 10, 2026. Its trailing P/E ratio is 7.3 and its net margin 82.4% (key statistics as of Nov 11, 2026).
What is ANAB's Alpha Score?
How it works →Alpha Score of 68 reflects moderate overall profile with moderate momentum, strong value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 11, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own ANAB?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 807K | $54.49M | +70% |
| D.E. Shaw David Shaw | 540K | $36.43M | -7% |
| Citadel Ken Griffin | 394K | $26.62M | +69% |
| Renaissance Technologies Jim Simons (founder) | 58K | $3.94M | -36% |
| Hussman Investment Trust John Hussman | 63K | $3.17M | +200% |
| Marshall Wace | 44K | $2.96M | -36% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are ANAPTYSBIO, INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Renton Hollings | Director | SELL | 5.0K | $249K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are ANAB's key statistics?
Key statistics as of Nov 11, 2026
How does ANAB's valuation compare with the Healthcare sector?
| Metric | ANAB | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 7.3 | 29.8 | 115 |
| Net margin | 82.37% | 3.60% | 175 |
| Return on equity | 894.97% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
ANAB price chart
Powered by TradingViewWhat does ANAPTYSBIO, INC do?
AnaptysBio Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. It advances antibody-based drug candidates that modulate immune pathways, including rosnilimab, a PD-1 agonist and pathogenic T cell depleter studied in rheumatoid arthritis; ANB033, a CD122 antagonist in trials for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator; and ANB032, a BTLA agonist for atopic dermatitis. The company has discovered and out-licensed therapeutic antibodies through financial collaborations, such as Jemperli (dostarlimab-gxly), a PD-1 antagonist to GSK for oncology indications, and imsidolimab, an IL-36 receptor antagonist to Vanda Pharmaceuticals for generalized pustular psoriasis. These partnerships provide eligibility for milestone payments and royalties. AnaptysBio Inc. maintains biopharma operations centered on internal clinical programs alongside its royalty-generating assets. Headquartered in San Diego, California, since 2005, it plays a key role in the immunology sector by targeting immune cell modulation to address unmet needs in autoimmune conditions.